LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 179

Search options

  1. Article ; Online: TREM2 variants that cause early dementia and increase Alzheimer's disease risk affect gene splicing.

    Kiianitsa, Kostantin / Lukes, Maria E / Hayes, Brian J / Brutman, Julianna / Valdmanis, Paul N / Bird, Thomas D / Raskind, Wendy H / Korvatska, Olena

    Brain : a journal of neurology

    2024  

    Abstract: Loss-of-function variants in the triggering receptor expressed on myeloid cells 2 (TREM2) are responsible for a spectrum of neurodegenerative disorders. In the homozygous state, they cause severe pathologies with early onset dementia, such as Nasu-Hakola ...

    Abstract Loss-of-function variants in the triggering receptor expressed on myeloid cells 2 (TREM2) are responsible for a spectrum of neurodegenerative disorders. In the homozygous state, they cause severe pathologies with early onset dementia, such as Nasu-Hakola disease (NHD) and behavioral variants of frontotemporal dementia (FTD), whereas heterozygous variants increase the risk of late-onset Alzheimer's disease (AD) and FTD. For over half of TREM2 variants found in families with recessive early onset dementia, the defect occurs at the transcript level via premature termination codons or aberrant splicing. The remaining variants are missense alterations thought to affect the protein; however, the underlying pathogenic mechanism is less clear. In this work, we tested whether these disease-associated TREM2 variants contribute to the pathology via altered splicing. Variants scored by SpliceAI algorithm were tested by a full-size TREM2 splicing reporter assay in different cell lines. The effect of variants was quantified by qRT-/RT-PCR and western blots. Nanostring nCounter was used to measure TREM2 RNA in the brains of NHD patients who carried spliceogenic variants. Exon skipping events were analyzed from brain RNA-Seq datasets available through the Accelerating Medicines Partnership for Alzheimer's Disease Consortium (AMP-AD). We found that for some NHD and early onset FTD-causing variants, splicing defects were the primary cause (D134G) or likely contributor to pathogenicity (V126G and K186N). Similar but milder effects on splicing of exons 2 and 3 were demonstrated for A130V, L133L and R136W enriched in patients with dementia. Moreover, the two most frequent missense variants associated with AD/FTD risk in European and African ancestries (R62H, 1% in Caucasians, and T96K, 12% in Africans) had splicing defects via excessive skipping of exon 2 and overproduction of a potentially antagonistic TREM2 protein isoform. The effect of R62H on exon 2 skipping was confirmed in three independent brain RNA-seq datasets. Our findings revealed an unanticipated complexity of pathogenic variation in TREM2, in which effects on post-transcriptional gene regulation and protein function often coexist. This necessitates the inclusion of computational and experimental analyses of splicing and mRNA processing for a better understanding of genetic variation in disease.
    Language English
    Publishing date 2024-01-16
    Publishing country England
    Document type Journal Article
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/awae014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Clinical approach to the patient with neurogenetic disease.

    Bird, Thomas D / Smith, Corrie O

    Handbook of clinical neurology

    2018  Volume 147, Page(s) 3–9

    Abstract: Neurogenetic diseases are surprisingly common. This chapter reviews a systematic approach to the evaluation of a patient thought to have such a disease. The emphasis is on first recognizing potential clues to the diagnosis contained in the family history ...

    Abstract Neurogenetic diseases are surprisingly common. This chapter reviews a systematic approach to the evaluation of a patient thought to have such a disease. The emphasis is on first recognizing potential clues to the diagnosis contained in the family history and presentation of symptoms. Ataxia, neuropathy, muscle weakness, dementia, epilepsy, and cognitive delay are all "reservoirs" of neurogenetic disease. A high index of suspicion for genetic causes and a thoughtful evaluation of simplex (sporadic) cases is often necessary. Then the physician can proceed to the differential diagnosis, genetic testing, and genetic counseling. A team approach including a genetic counselor is usually the best strategy.
    MeSH term(s) Family Health ; Genetic Counseling ; Genetic Predisposition to Disease/genetics ; Genetic Testing/methods ; Humans ; Nervous System Diseases/diagnosis ; Nervous System Diseases/genetics ; Nervous System Diseases/therapy
    Language English
    Publishing date 2018
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 0072-9752
    ISSN 0072-9752
    DOI 10.1016/B978-0-444-63233-3.00001-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: TREM2 and neurodegenerative disease.

    Bird, Thomas D

    The New England journal of medicine

    2013  Volume 369, Issue 16, Page(s) 1568

    MeSH term(s) Alzheimer Disease/genetics ; Animals ; Humans ; Membrane Glycoproteins/genetics ; Mutation ; Mutation, Missense ; Receptors, Immunologic/genetics
    Chemical Substances Membrane Glycoproteins ; Receptors, Immunologic
    Language English
    Publishing date 2013-10-17
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1306509#SA5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Progress in Amyotrophic Lateral Sclerosis Gene Discovery: Reflecting on Classic Approaches and Leveraging Emerging Technologies.

    Smukowski, Samuel N / Maioli, Heather / Latimer, Caitlin S / Bird, Thomas D / Jayadev, Suman / Valdmanis, Paul N

    Neurology. Genetics

    2022  Volume 8, Issue 3, Page(s) e669

    Abstract: Amyotrophic lateral sclerosis (ALS) is the most prominent motor neuron disease in humans. Its etiology consists of progressive motor neuron degeneration resulting in a rapid decline in motor function starting in the limbs or bulbar muscles and eventually ...

    Abstract Amyotrophic lateral sclerosis (ALS) is the most prominent motor neuron disease in humans. Its etiology consists of progressive motor neuron degeneration resulting in a rapid decline in motor function starting in the limbs or bulbar muscles and eventually fatally impairing central organs most typically resulting in loss of respiration. Pathogenic variants in 4 main genes,
    Language English
    Publishing date 2022-04-27
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2818607-2
    ISSN 2376-7839
    ISSN 2376-7839
    DOI 10.1212/NXG.0000000000000669
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Aberrant splicing of PSEN2, but not PSEN1, in individuals with sporadic Alzheimer's disease.

    Course, Meredith M / Gudsnuk, Kathryn / Keene, C Dirk / Bird, Thomas D / Jayadev, Suman / Valdmanis, Paul N

    Brain : a journal of neurology

    2022  Volume 146, Issue 2, Page(s) 507–518

    Abstract: Alzheimer's disease is the most common neurodegenerative disease, characterized by dementia and premature death. Early-onset familial Alzheimer's disease is caused in part by pathogenic variants in presenilin 1 (PSEN1) and presenilin 2 (PSEN2), and ... ...

    Abstract Alzheimer's disease is the most common neurodegenerative disease, characterized by dementia and premature death. Early-onset familial Alzheimer's disease is caused in part by pathogenic variants in presenilin 1 (PSEN1) and presenilin 2 (PSEN2), and alternative splicing of these two genes has been implicated in both familial and sporadic Alzheimer's disease. Here, we leveraged targeted isoform-sequencing to characterize thousands of complete PSEN1 and PSEN2 transcripts in the prefrontal cortex of individuals with sporadic Alzheimer's disease, familial Alzheimer's disease (carrying PSEN1 and PSEN2 variants), and controls. Our results reveal alternative splicing patterns of PSEN2 specific to sporadic Alzheimer's disease, including a human-specific cryptic exon present in intron 9 of PSEN2 as well as a 77 bp intron retention product before exon 6 that are both significantly elevated in sporadic Alzheimer's disease samples, alongside a significantly lower percentage of canonical full-length PSEN2 transcripts versus familial Alzheimer's disease samples and controls. Both alternatively spliced products are predicted to generate a prematurely truncated PSEN2 protein and were corroborated in an independent cerebellum RNA-sequencing dataset. In addition, our data in PSEN variant carriers is consistent with the hypothesis that PSEN1 and PSEN2 variants need to produce full-length but variant proteins to contribute to the onset of Alzheimer's disease, although intriguingly there were far fewer full-length transcripts carrying pathogenic alleles versus wild-type alleles in PSEN2 variant carriers. Finally, we identify frequent RNA editing at Alu elements present in an extended 3' untranslated region in PSEN2. Overall, this work expands the understanding of PSEN1 and PSEN2 variants in Alzheimer's disease, shows that transcript differences in PSEN2 may play a role in sporadic Alzheimer's disease, and suggests novel mechanisms of Alzheimer's disease pathogenesis.
    MeSH term(s) Humans ; Alzheimer Disease/genetics ; Amyloid beta-Protein Precursor/genetics ; Mutation ; Presenilin-2/genetics ; Presenilin-1/genetics ; Neurodegenerative Diseases
    Chemical Substances Amyloid beta-Protein Precursor ; Presenilin-2 ; Presenilin-1 ; PSEN2 protein, human
    Language English
    Publishing date 2022-08-21
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/awac294
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Molecular genetic testing for hereditary ataxia: What every neurologist should know.

    Wallace, Stephanie E / Bird, Thomas D

    Neurology. Clinical practice

    2017  Volume 8, Issue 1, Page(s) 27–32

    Abstract: Purpose of review: Because of extensive clinical overlap among many forms of hereditary ataxia, molecular genetic testing is often required to establish a diagnosis. Interrogation of multiple genes has become a popular diagnostic approach as the cost of ...

    Abstract Purpose of review: Because of extensive clinical overlap among many forms of hereditary ataxia, molecular genetic testing is often required to establish a diagnosis. Interrogation of multiple genes has become a popular diagnostic approach as the cost of sequence analysis has decreased and the number of genes associated with overlapping phenotypes has increased. We describe the benefits and limitations of molecular genetic tests commonly used to determine the etiology of hereditary ataxia.
    Recent findings: There are more than 300 hereditary disorders associated with ataxia. The most common causes of hereditary ataxia are expansion of nucleotide repeats within 7 genes:
    Summary: The majority of individuals with hereditary ataxias have nucleotide repeat expansions, pathogenic variants that are not detectable with clinical exome sequencing. Multigene panels that include specific assays to determine nucleotide repeat lengths should be considered first in individuals with hereditary ataxia.
    Language English
    Publishing date 2017-05-10
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2645818-4
    ISSN 2163-0933 ; 2163-0402
    ISSN (online) 2163-0933
    ISSN 2163-0402
    DOI 10.1212/CPJ.0000000000000421
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Mutations in the SIGMAR1 gene cause a distal hereditary motor neuropathy phenotype mimicking ALS: Report of two novel variants.

    Ma, Maxwell T / Chen, Dong-Hui / Raskind, Wendy H / Bird, Thomas D

    Neuromuscular disorders : NMD

    2020  Volume 30, Issue 7, Page(s) 572–575

    Abstract: Distal hereditary motor neuropathy (dHMN) is an inherited neuromuscular disease characterized by symmetric distal weakness and atrophy without sensory changes. There are about thirty known genes associated with dHMN, but together they explain only about ... ...

    Abstract Distal hereditary motor neuropathy (dHMN) is an inherited neuromuscular disease characterized by symmetric distal weakness and atrophy without sensory changes. There are about thirty known genes associated with dHMN, but together they explain only about a third of cases. Mutations in the sigma non-opioid intracellular receptor 1 gene (SIGMAR1) has been linked to autosomal recessive dHMN with pyramidal signs in several families. This phenotype can mimic amyotrophic lateral sclerosis (ALS). We report a 39-year-old man who was referred to our ALS clinic with distal motor weakness and hyperreflexia. Whole exome sequencing identified two novel variants in the SIGMAR1 gene in the proband. Targeted Sanger sequencing of asymptomatic family members confirmed that each carried one of these two variants. Our findings expand the number of known SIGMAR1 pathogenic variants associated with dHMN, which should be clinically distinguished from ALS.
    MeSH term(s) Adult ; Amyotrophic Lateral Sclerosis/diagnosis ; Diagnosis, Differential ; Family ; Genetic Predisposition to Disease ; Humans ; Male ; Muscular Atrophy, Spinal/diagnosis ; Muscular Atrophy, Spinal/genetics ; Mutation/genetics ; Pedigree ; Phenotype ; Receptors, sigma/genetics ; Sigma-1 Receptor
    Chemical Substances Receptors, sigma
    Language English
    Publishing date 2020-05-23
    Publishing country England
    Document type Case Reports ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1077681-3
    ISSN 1873-2364 ; 0960-8966
    ISSN (online) 1873-2364
    ISSN 0960-8966
    DOI 10.1016/j.nmd.2020.05.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Genetic factors in neurodegenerative diseases.

    Tsuang, Debby W / Bird, Thomas D

    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics

    2016  Volume 174, Issue 1, Page(s) 3–4

    MeSH term(s) Animals ; Humans ; Neurodegenerative Diseases/etiology ; Neurodegenerative Diseases/genetics
    Language English
    Publishing date 2016-10-22
    Publishing country United States
    Document type Editorial ; Introductory Journal Article ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2143866-3
    ISSN 1552-485X ; 1552-4841
    ISSN (online) 1552-485X
    ISSN 1552-4841
    DOI 10.1002/ajmg.b.32504
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Approaches to the patient with neurogenetic disease.

    Bird, Thomas D

    Clinics in laboratory medicine

    2010  Volume 30, Issue 4, Page(s) 785–793

    Abstract: The clinical practice of neurogenetics is complex, challenging, and rewarding. Several guidelines are helpful. This article briefly focuses on 8 aspects of clinical neurogenetics, namely (1) factors suggesting the presence of a genetic disease, (2) ... ...

    Abstract The clinical practice of neurogenetics is complex, challenging, and rewarding. Several guidelines are helpful. This article briefly focuses on 8 aspects of clinical neurogenetics, namely (1) factors suggesting the presence of a genetic disease, (2) nonspecific categories that may be hiding neurogenetic diseases, (3) importance of family history, (4) assessment of sporadic cases, (5) genetic counseling, (6) genetic testing, (7) available information resources, and (8) integration of the clinical neurogenetic strategy.
    MeSH term(s) Genetic Counseling ; Genetic Predisposition to Disease ; Genetic Testing ; Humans ; Nervous System Diseases/diagnosis ; Nervous System Diseases/genetics ; Nervous System Diseases/therapy ; Pedigree
    Language English
    Publishing date 2010-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604580-7
    ISSN 1557-9832 ; 0272-2712
    ISSN (online) 1557-9832
    ISSN 0272-2712
    DOI 10.1016/j.cll.2010.07.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Neurogenetics: Five new things.

    Jayadev, Suman / Smith, Corrine O / Bird, Thomas D

    Neurology. Clinical practice

    2018  Volume 1, Issue 1, Page(s) 41–48

    Abstract: Clinical neurology has benefitted greatly from recent remarkable advances in molecular genetics. In 1991, we could approximate a patient's risk for Huntington disease (HD) based only on linkage analysis. Now, 20 years later, not only can we identify the ... ...

    Abstract Clinical neurology has benefitted greatly from recent remarkable advances in molecular genetics. In 1991, we could approximate a patient's risk for Huntington disease (HD) based only on linkage analysis. Now, 20 years later, not only can we identify the HD mutation with certainty, we can do the same with several hundred diseases. Whole genome or exome sequencing will soon allow for one-step interrogation of multiple genes for an even larger range of diseases. The recognition of these genes and their associated proteins in combination with new technology has led to creative new approaches to treatment. The challenge for the practicing neurologist is to provide clinically relevant and accurate interpretation of the genetic test results, with successfully treating once "incurable" neurogenetic diseases our ultimate goal.
    Language English
    Publishing date 2018-02-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2645818-4
    ISSN 2163-0933 ; 2163-0402
    ISSN (online) 2163-0933
    ISSN 2163-0402
    DOI 10.1212/CPJ.0b013e31823c0f5f
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top